MRI for Glioblastoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial uses MRI scans (Magnetic Resonance Imaging) to study brain tumors in patients with glioblastoma, a severe type of brain cancer. The goal is to identify which patients might benefit most from bevacizumab, a common but costly treatment. Participants must have a glioblastoma tumor that can be surgically removed and hasn't returned within three months of completing radiation therapy. The trial requires an MRI scan before surgery to observe specific markers in the brain. This research could help tailor treatments to individual patients, potentially improving outcomes. As an unphased trial, this study offers a unique opportunity to contribute to personalized treatment strategies for glioblastoma.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What prior data suggests that MRI is safe for studying brain tumor biology in glioblastoma patients?
Previous studies have shown that MRI (magnetic resonance imaging) has been used safely in various medical procedures, including those for brain tumors. Research indicates that using MRI during glioma surgery doesn't cause major safety issues, although it may extend the surgery by about 42 minutes on average. Importantly, there were no significant reports of harmful side effects from the MRI itself.
In this trial, MRI is a common imaging technique used to better understand brain tumors. Findings suggest that MRI is well-tolerated, particularly because it is non-invasive. The main purpose of MRI here is to provide detailed images of the brain, aiding doctors in making better treatment decisions. Overall, based on existing data, participating in a trial using MRI should not pose significant safety concerns.12345Why are researchers excited about this trial?
Researchers are excited about using MRI for glioblastoma because it offers a non-invasive way to assess the tumor before surgery. Unlike traditional methods that might rely on invasive biopsies, MRI provides detailed images of the brain, helping surgeons plan procedures more accurately and potentially improving outcomes. This technique could lead to better-targeted treatments by allowing doctors to understand the tumor's characteristics and location without making an incision.
What evidence suggests that MRI is effective for studying glioblastoma?
Research shows that advanced MRI scans enhance understanding of glioblastoma and link these insights to patient outcomes. In this trial, participants will undergo an MRI scan during the screening process. MRI can predict how long a patient might live without cancer worsening and their overall survival. One study found that MRI accurately identifies patients with the condition 90% of the time and those without it 88% of the time. These findings suggest that MRI is a valuable tool in determining which patients might benefit from treatments like bevacizumab, helping to customize therapies and improve outcomes for glioblastoma patients.46789
Who Is on the Research Team?
Benjamin M. Ellingson
Principal Investigator
UCLA / Jonsson Comprehensive Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 with new or returning glioblastoma, a type of brain tumor. Participants must have tumors larger than 1.5 mL that can be surgically removed and should not have had radiation therapy within the last three months.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo one MRI scan over approximately 1 hour prior to surgery
Follow-up
Participants are monitored for safety and effectiveness after imaging and surgery
What Are the Treatments Tested in This Trial?
Interventions
- Biospecimen Collection
- Magnetic Resonance Imaging
Magnetic Resonance Imaging is already approved in United States for the following indications:
- Non-small cell lung cancer with KRAS G12C mutation
- Advanced colorectal cancer that is wild-type RAS
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jonsson Comprehensive Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator